Mo 화학기상증착에 있어서 불순물 농도에 미치는 증착조건의 영향

배상석,서성교,홍은식,김승모,조미정,한혜정,이두성,김세훈,민석홍 국립7개대학공동논문집간행위원회 2001 공업기술연구 Vol.1 No.-

The thermal decomposition process of Mo(CO)_6 on chemical vapor deposition was investigated by analyzing the effects of deposition temperature, pressure, and reaction gas on the phase change of deposited films. Mo_2C was deposited at or below 350℃ due to the incompleteness of thermal decomposition of Mo(CO)_6, but Mo films was successfully deposited at 400℃ or higher temperatures. The variation of deposition pressure did not change the dependence of decomposition process on deposition temperature. The activation energy of surface reaction was 5.8 ㎉/mole.

실과의 NIE적용 진로교육이 아동의 진로성숙에 미치는 효과

정모근,김은자 부산교육대학교 교육대학원 2003 논문집 Vol.5 No.-

The purpose of this study is to figure out the system and the direction of Career Education through the analysis of the Practical Art Education School Work and also is to find out the model and the strategy of Career Education applied to NIE. Among of them, the newspaper data which is proper as studying subjects including the method th reach in NIE studying was only used in classes about sixth Practical Arts Education, as the departure of occupations and works, cooking to make easily and taking care of pets. The subject of this study was choosen two class of six grade in Elementary School in Busan, which was separated between a group of experimentation and a group of comparison. The member of each group is 40 and following is summary. 1. It was more efficient to improve child's Career Attitude and Career Ability using Career Education applied to NIE than normal one. 2. There were no relationship between sexes of children about the effect of child's Career Attitude and Career Ability using Career Education applied to NIE. 3. It didn't depend on the grade level of children about the effect of child's Career Attitude and Career Ability using Career Education applied to NIE. To sum up. it was more efficient about Career growth to choose Career Education than usual one not to be related to child's sex or grade level.

경남지역 건강검진자에서의 혈청지질에 관한 연구

정준훈,박현모,류재오,조동자,표미순,오은경 한국건강관리협회 2000 건협 Report Vol.3 No.-

저온 체외순환 후 체온과 혈액가스의 변화

윤은숙,정창영,임웅모 全南大醫大 1985 전남의대학술지 Vol.22 No.4

진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472) 연구배경 : 일차항암화학요법 후에 생존의 이득을 얻었음에도 불구하고 비소세포폐암 환자들의 대다수가 결국은 재발하거나 진행성 병변을 보인다. 이에 저자들은 기존의 여러 연구에서 보고 된 구제요법으로서 docetaxel의 항암효과와 비교적 적은 독성의 결과를 바탕으로,platinum을 근거로 한 항암화학요법을 시행 밖았으나 개발되거나 진행된 비소세포폐암 환자들을 대상으로 docetaxel 단독요법의 치료효과와 부작용에 대하여 알아보고자 하였다. 방법 : 조직학적으로 비소세포폐암으로 진단을 받고 platinum을 근거로 한 항암화학요법을 받았으나 재발 또는 진행성 병변을 보인 31명의 환자들을 대상으로 docetaxel 75 mg/m² 또는 100 mg/m²을 3주마다 정주하였다. 임상기록을 통한 후향적인 방법으로 분석하였다. 결과 : 1) 재발 또는 진행성 병변을 보인 31명중 남녀 비는 24:7이고 중앙연령은 60세였다. 2) 반응평가로 완전 관해는 없었고 부분관해는 14명(45.2%), 불변이 10명(32.3%), 진행이 7명(22.6%)으로 전체적인 반응율은 45.2%이었다. 3)중앙생존기간은 12.5개월(95% 신뢰구간: 7.3개월 17.6개월) 이었고, 1년 생존율은 52%였다. 무진행생존기간의 중앙값은 3.0개월(95%신뢰구간: 1.6개월 -4.5개월)이며, 반응군에서의 중앙반응지속피간은 3.7개월(95% 신뢰구간: 3.0개월 - 4.4개월)이었다. 4) 60세 미만인 경우(20.1 months vs 6.6 months. p=0,0105), 조직학적 아형이 선암일 경우(25.6 months vs 7.9 months, 0=0.0055) 통계적으로 유의한 생존기간의 증가가 있었다. 5) 부작용으로 3도 이상의 백혈구 감소증은 12명(38.7%),호중구 감소증에 동반된 발열은 6명(19.3%),감염이 동반된 호중구 감소증은 4명(12.9%)에서 발생했다. 치료와 관련되어 1명이 사망하였다. 6) Docetaxel 용량에 따른 생존기간의 차이나 독성의 차이는 없었다. 결론 : Platinum을 근거로 하는 항암화학요법으로 치료받은 후 재발 또는 진행성 병변을 보이는 비소세포폐암환자들에게 docetaxel을 투여하는 것은 비교적 안전하고 효과적인 항암치료법으로 사료된다.

부착성 동물세포의 Scale-up을 위한 방법의 개발

김승모,송상호,최명락,유은정,임현수 여수대학교 1997 論文集 Vol.11 No.2

This study was a protocol of serial propagation for anchorage-dependent animal cell. Vero. by the optimization of trypsin and EDTA concentration in T-25 flask. Commen enzymetic treatment in PBS solution has been modified for a high degree of cell datachment from T-25 flask and for transfer of a maximum number of viable cells from one culture to the next during the scale up process. Culture of Vero cells were washed with Dulbecco's modified Eagle's medium(DMEM) and then exposed to DMEM containing trypsin(0.025%) and EDTA(0.16%). Up to 90% of cells detached from bottom of flask and the viability of cells was greater than 93%. The protocol using the developed method was successfully applied to the next 10 times scale up process. Consequently, the developed method changed multiple steps of processes to one step, so it promised th easy scale-up and low cost demand of animal cell culture.

진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암연구소 2006 암연구소 업적집 Vol.5 No.-

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472)

十全大補湯이 抗癌劑를 投與한 생쥐의 胸腺細胞에 미치는 影響

金大根,殷載淳,全薰,宋正模 대한본초학회 1998 大韓本草學會誌 Vol.13 No.2

The purpose of this research was to investigate effects of Sipjeon-Daebo-Tang(SDT) on thymocytes of anti-tumor drugs administered mice. DNA fragmentation, mitochondrial transmembrane potential and subpopulation were tested using a flow cytometry. and the cell viability was tested using a MTT assay. Etoposide, vincristine and doxorubicin enhanced DNA fragmentation and reduced mitochondrial transmembrane potential of thymocytes, but SDT recoverd the action of vincristine and doxorubicin. Etoposide or vincristine decreased the population of CD4 single positive cell in thymocytes, but SDT enhanced the population of CD4+ single positive cell. Etoposide, vincristine and doxorubicin decreased the cell viability of thymocytes, but SDT enhanced the cell viability. These results suggest that SDT has a regulative function of thymocytes in anti-tumor drugs administered mice.

四物湯이 腹腔 Macrophage 의 貪食能에 미치는 影響

全熏,殷載淳,宋正模 대한본초학회 1999 大韓本草學會誌 Vol.14 No.2

Samultang(SMT) consists of Rehmanniae Radix Preparata, Paeoniae Radix Alba, Cnidii Rhizoma and Angelicae Gigantis Radix. SMT enhanced the lucigenin chemiluminescence and the engulfment of fluorescein-conjugated E. coli particles and did not affect the production of nitric oxide in murine peritoneal macrophage. SMT enhanced the production of γ-interferon, interleukin-2 and the cell viability in murine thymocyte, but did not affect the production of interleukin-4. These results indicate that SMT enhances the phagocytosis of macrophage via the stimulation of γ-interferon production in T_H1 cells.

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

장필순,강현모,이정은,권선중,안진영,이연선,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/㎡ followed by an infusion of gemcitabine 1000mg/㎡ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI l-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351) 배경 : Gemcitabine, paditaxel, docetaxel, vinorelbine, ir-rinotecan 새로운 항종양제의 출현으로 일차 치료의효과가 증대 되고 있고 재발시에도 좋은 신체 활동도를 보이고 있어서 이차 치료의 대상군도 늘어나는 효과를 보이고 있다. 치료의 필요성은 증대 되고 있지만 현재까지 표준 치료가 확립되지 않은 상황에서 Gem-citabine과Vinorelbine모두 독성이 강하지 않아서 혼합 요법이 가능한 장점이 있고 비소세포 폐암에 대한효과도 입증이 되어있어서 본 연구는 반응이 없거나 반응을 보인후에 재발된 진행된 비소세포 폐암에 ge-mdtabine과 vinorelbine 흔합 요법을 시행하여서 치료 반응률과 생존율 그리고 부작용을 평가하였다. 대상 및 방법 :2000년 6월부터 2004년 3월까지 충남대학교병원에내원하여 진행성 비소세포 폐암 IIIA/IIIB, IV로 진단을 받고 일차 항암화학요법치료를 받은 환자중에 초기 치료에 반응이 없거나, 치료에 반응이 있었으나 병이 진행된 환자로 추적 관찰 기간이 6개월 이상인 환자를 대상으로 생존율과 반응률 그리고 독성을 분석하였다. 결과 : 총 치료 반응률은 17%. 반응 유지기간의 중앙값은 3.1개월(1-10개월)이었고 생존기간의 중앙값은 8.2개월 (1-23개월) 그리고 1년 생존율은 35%였다. 항암화학요법에 의한 독성은 3도 이상의 중성구 감소가 12%, 오심과 구토가 12.5% 였다. 결론 : 일차 치료에 반응이 없거나 재발한 비소세포 폐암환자의 이차 치료로 gemcitabine과 vinorelbine 혼합요법은 효과적이라고 생각되며 향후 3상 연구를 통한다른 약제와의 비교 연구가 필요하다고 생각된다.